IP Library Granted Patent US 8,168,429
Granted Patent B2
US 8,168,429 · App. 10/587,014 · Granted May 1, 2012

Method of amplifying hematopoietic stem cell and hematopoietic progenitor cell

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,168,429
App. No.
10/587,014
Granted
May 1, 2012
Kind
B2
Abstract

The present invention provides useful means in an expansion culture system for a hematopoietic cell (hematopoietic stem cell, hematopoietic progenitor cell). Specifically, the present invention provides a composition for expanding a hematopoietic cell (hematopoietic stem cell, hematopoietic progenitor cell) containing recombinant human serum albumin; a serum-free medium for expanding a hematopoietic cell containing a basal medium and recombinant human serum albumin; a method of expanding a hematopoietic cell comprising culturing a hematopoietic cell in a serum-free medium containing recombinant human serum albumin, and a culture of a hematopoietic cell that can be obtained by the expansion method.

Claims (26)

1. A method of expanding a hematopoietic stem cell, which comprises

(i) forming a first solution comprising cholesterol,

(ii) adding the first solution to a serum-free medium to form a second solution, wherein the second solution further comprises lecithin, tocopherol, stem cell factor, thrombopoietin, Flt3/Flk2 ligand, interleukin-6, soluble interleukin-6 receptor, and a recombinant human serum albumin (rHSA)-containing composition obtained from yeast, and

(iii) culturing a hematopoietic stem cell in the second solution to expand the hematopoietic stem cell and to suppress differentiation of the hematopoietic stem cell.

2. The method of claim 1 , which further comprises isolating the hematopoietic stem cell.

3. The method of claim 2 , wherein the hematopoietic stem cell is derived from umbilical cord blood.

4. The method of claim 2 , wherein the expanded hematopoietic stem cell is selected from the group consisting of CD34 + /CD38 − , CD34 + /DR − , CD34 + /CD90 + , CD34 + /CD117 + , CD34 + /CD123 + , and CD34 + /CD133 + .

5. The method of claim 2 , wherein the expanded hematopoietic stem cell is CD34 +/CD 38 − /DR − .

6. The method of claim 2 , wherein the first solution further comprises ethanol.

7. The method of claim 2 , wherein the expanded hematopoietic stem cell is CD34 + /CD38 − .

8. The method of claim 1 , wherein the hematopoietic stem cell is derived from umbilical cord blood.

9. The method of claim 1 , wherein the expanded hematopoietic stem cell is CD34 + /CD38 − /DR − .

10. The method of claim 1 , wherein the serum-free medium comprises a basal medium.

11. The method of claim 10 , which further comprises administering the hematopoietic stem cell to a patient.

12. The method of claim 11 , wherein the patient is undergoing cell transplant therapy.

13. The method of claim 11 , wherein the hematopoietic stem cell is derived from umbilical cord blood.

14. The method of claim 11 , wherein the expanded hematopoietic stem cell is selected from the group consisting of CD34 + /CD38 − , CD34 + /DR − , CD34 + /CD90 + , CD34 + /CD117 + , CD34 + /CD123 + , and CD34 + /CD133 + .

15. The method of claim 11 , wherein the expanded hematopoietic stem cell is CD34 + /CD38 − /DR − .

16. The method of claim 11 , wherein the first solution further comprises ethanol.

17. The method of claim 11 , wherein the expanded hematopoietic stem cell is CD34+/CD38−.

18. The method of claim 1 , wherein the first solution further comprises ethanol.

19. The method of claim 1 , wherein the expanded hematopoietic stem cell is CD34 + /CD38 − .

20. A method of expanding a hematopoietic stem cell, which comprises

(i) forming a first solution comprising cholesterol,

(ii) adding the first solution to a serum-free medium to form a second solution, wherein the second solution further comprises lecithin, tocopherol, stem cell factor, thrombopoietin, Flt3/Flk2 ligand, interleukin-6, soluble interleukin-6 receptor, and a recombinant human serum albumin (rHSA)-containing composition obtained from yeast, and

(iii) culturing a hematopoietic stem cell in the second solution to expand the hematopoietic stem cell and to suppress differentiation of the hematopoietic stem cell, wherein the expanded hematopoietic stem cell is selected from the group consisting of CD34 + /CD38 − , CD34 + /DR − , CD34 + /CD90 + , CD34 + /CD117 + , CD34 + /CD123 + , and CD34 + /CD133 + .

Assignments (2)
CHANGE OF NAME Recorded Apr 17, 2008
From: MITSUBISHI PHARMA CORPORATION
To: MITSUBISHI TANABE PHARMA CORPORATION
Reel/Frame 020838/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2007
From: HATSUYAMA, ASAKO; ITO, KIMINARI; NAKAHATA, TATSUTOSHI
To: MITSUBISHI PHARMA CORPORATION
Reel/Frame 019228/0567 →